23andMe Investor Presentation Deck

Phase 1 Study of 23ME'610 in Patients with Locally Advanced or Metastatic Solid Malignancies 1 Phase 1 Patients with locally advanced, unresectable or metastatic solid tumors that have progressed after or are inappropriate for standard therapy Study Design Y Openlabel Non- Randomized Part A (n = 26) Monotherapy Dose Escalation (IV Infusion Q3W) Accelerated Titration 3+3 Cohorts x RP2D / MTD Multi-center Part B (n = 75) Expansion Cohort Expansion Cohort Expansion Cohort Expansion Cohort Expansion Cohort Primary Objectives Part A: Safety (DLTS, AES) Part B: Efficacy (ORR) Secondary and Exploratory Efficacy (ORR [RECIST and iRECIST]), DOR, PFS, OS) and Safety Pharmacokinetics Pharmacodynamic biomarkers Abbreviations: AEs: Adverse Events; DLT: Dose limiting toxicity; DOR: duration of response; IV: intravenous; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression Free Survival; Q3W: every three weeks; RECIST: Response Evaluation Criteria in Solid Tumors; RP2D: Recommended Phase 2 Dose Copyright © 2022 23and Me, Inc. 23andMe 47

View entire presentation